INDSWIFT LABORATORIES
Quarterly Results Analysis [Sep2024]
INDSWIFT LABORATORIES Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹12 Cr | ₹33 Cr | ₹393 Cr | ₹288 Cr | ₹290 Cr | ₹310 Cr | ₹304 Cr | ₹313 Cr |
Expenses | ₹24 Cr | ₹43 Cr | ₹431 Cr | ₹236 Cr | ₹224 Cr | ₹250 Cr | ₹241 Cr | ₹259 Cr |
Operating Income | ₹-12 Cr | ₹-10 Cr | ₹-37 Cr | ₹52 Cr | ₹66 Cr | ₹60 Cr | ₹64 Cr | ₹54 Cr |
Other Income | ₹13 Cr | ₹11 Cr | ₹25 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹10 Cr | ₹8 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹-11 Cr | ₹21 Cr | ₹21 Cr | ₹20 Cr | ₹22 Cr | ₹22 Cr |
Depreciation | ₹0 Cr | ₹0 Cr | ₹13 Cr | ₹14 Cr | ₹13 Cr | ₹14 Cr | ₹9 Cr | ₹15 Cr |
Profit Before Tax | ₹1 Cr | ₹1 Cr | ₹373 Cr | ₹24 Cr | ₹39 Cr | ₹32 Cr | ₹16 Cr | ₹24 Cr |
Profit After Tax | ₹0 Cr | ₹1 Cr | ₹239 Cr | ₹20 Cr | ₹32 Cr | ₹17 Cr | ₹-25 Cr | ₹28 Cr |
EPS | ₹0.07 | ₹0.16 | ₹40.42 | ₹3.29 | ₹5.36 | ₹2.92 | ₹-4.25 | ₹4.65 |
Industry Peers & Returns | 1W | 1M | 1Y |
INDSWIFT LABORATORIES | 0.7% | 9.1% | 19.9% |
SUN PHARMACEUTICAL INDUSTRIES | 1% | 4.6% | 47.5% |
CIPLA | -1.1% | -0.3% | 20.7% |
DR REDDYS LABORATORIES | 2.2% | 12.1% | 21.6% |
ZYDUS LIFESCIENCES | -2.7% | 0.8% | 43.8% |
DIVIS LABORATORIES | 1% | -3.2% | 59.3% |
MANKIND PHARMA | 0.8% | 12.8% | 52.4% |
TORRENT PHARMACEUTICALS | -1.5% | 5.9% | 55% |
LUPIN | 0.9% | 7.2% | 72.7% |
INDSWIFT LABORATORIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -63.95 % |
Y-o-Y | -95.87 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹12 Cr | -63.95 | |
Jun2024 | ₹33 Cr | -91.57 | |
Mar2024 | ₹393 Cr | 36.81 | |
Dec2023 | ₹288 Cr | -0.76 | |
Sep2023 | ₹290 Cr | -6.65 | |
Jun2023 | ₹310 Cr | 2.00 | |
Mar2023 | ₹304 Cr | -2.70 | |
Dec2022 | ₹313 Cr | - |
INDSWIFT LABORATORIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹-12 Cr | Negative | |
Jun2024 | ₹-10 Cr | Negative | |
Mar2024 | ₹-37 Cr | Negative | |
Dec2023 | ₹52 Cr | -21.32 | |
Sep2023 | ₹66 Cr | 8.95 | |
Jun2023 | ₹60 Cr | -5.30 | |
Mar2023 | ₹64 Cr | 18.44 | |
Dec2022 | ₹54 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | -98.65% | Negative | |
Jun2024 | -29.37% | Negative | |
Mar2024 | -9.48% | Negative | |
Dec2023 | 17.98% | -20.72 | |
Sep2023 | 22.68% | 16.73 | |
Jun2023 | 19.43% | -7.17 | |
Mar2023 | 20.93% | 21.76 | |
Dec2022 | 17.19% | - |
INDSWIFT LABORATORIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -60.46 % |
Y-o-Y | -98.75 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹0 Cr | -60.46 | |
Jun2024 | ₹1 Cr | -99.58 | |
Mar2024 | ₹239 Cr | 1,123.16 | |
Dec2023 | ₹20 Cr | -38.65 | |
Sep2023 | ₹32 Cr | 82.97 | |
Jun2023 | ₹17 Cr | Positive | |
Mar2023 | ₹-25 Cr | Negative | |
Dec2022 | ₹28 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 9.87 % |
Y-o-Y | -69.61 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 3.34 % | 9.87 | |
Jun2024 | 3.04 % | -94.99 | |
Mar2024 | 60.73 % | 794.40 | |
Dec2023 | 6.79 % | -38.22 | |
Sep2023 | 10.99 % | 95.90 | |
Jun2023 | 5.61 % | Positive | |
Mar2023 | -8.23 % | Negative | |
Dec2022 | 8.83 % | - |
INDSWIFT LABORATORIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -56.25 % |
Y-o-Y | -98.69 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹0.07 | -56.25 | |
Jun2024 | ₹0.16 | -99.60 | |
Mar2024 | ₹40.42 | 1,128.57 | |
Dec2023 | ₹3.29 | -38.62 | |
Sep2023 | ₹5.36 | 83.56 | |
Jun2023 | ₹2.92 | Positive | |
Mar2023 | ₹-4.25 | Negative | |
Dec2022 | ₹4.65 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD